Dr. Costa on Triplet of Venetoclax, Carfilzomib, and Dexamethasone in Multiple Myeloma
June 3rd 2018Luciano J. Costa, MD, PhD, associate professor of medicine, Blood and Marrow Transplantation and Cell Therapy Program, University of Alabama at Birmingham School of Medicine, discusses phase II findings with the triplet regimen of venetoclax (Venclexta), carfilzomib (Kyprolis), and dexamethasone in patients with relapsed/refractory multiple myeloma. Costa shared this insight in an interview with OncLive during the 2018 ASCO Annual Meeting.
Dr. Urbanic on the Evolution of Radiation in NSCLC
May 25th 2018James Urbanic, MD, associate professor, Radiation Medicine and Applied Sciences, University of California, San Diego, discusses the evolution of radiation therapy in the treatment of patients with oligometastatic non–small cell lung cancer.
Dr. Harshman on Earlier Use of Immunotherapy in RCC
May 18th 2018Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses moving immunotherapy earlier in the line of therapy for patients with renal cell carcinoma (RCC).
Dr. Flinn on FDA Approval of Tisagenlecleucel in DLBCL
May 2nd 2018Ian W. Flinn, MD, PhD, director of Lymphoma Research, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of the chimeric antigen receptor T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma.
Dr Shannon Maude: The Novelty of CAR T Treatments Requires Patient Education
May 1st 2018Chimeric antigen receptor (CAR) T-cell treatments are still new enough that there are still unknown regarding long-term side effects, which is something patients need to understand before they undergo treatment, said Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.
Dr Stephen Schuster: Unique CAR T Toxicities Require Provider Education
April 17th 2018Since patients who receive CAR T-cell therapy experience unique adverse events, there will need to be education for providers who care for these patients, explained Stephen Schuster, MD, of the Perelman School of Medicine.
Dr. Goldberg on Sequencing Following Treatment With Osimertinib in NSCLC
April 12th 2018Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses sequencing after therapy with osimertinib (Tagrisso) in EGFR-positive non–small cell lung cancer.
Dr Nina Shah Outlines New Treatments Being Studied for Multiple Myeloma
April 7th 2018While there has been progress with using chimeric antigen receptor (CAR) T cells to treat multiple myeloma, these treatments aren’t ready for prime time, said Nina Shah, MD, associate professor, University of California, San Francisco, School of Medicine.
Dr. Park on CD19-Directed CAR T-Cell Therapy in Patients With ALL
April 6th 2018Jae Park, MD, hematologist oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy in adult patients with acute lymphoblastic leukemia (ALL).
Jim Schwartz Discusses How His Practice Will Handle Using CAR T-Cell Treatments
March 26th 2018Jim Schwartz, RPh, president of the National Community Oncology Dispensing Association and executive director of pharmacy operations for Texas Oncology, discusses how his practice will handle using CAR T-cell therapies to treat patients.
Dr. Bachier Discusses CAR T-Cell Therapy and Stem Cell Transplant
March 13th 2018Carlos R. Bachier, MD, program director of Sarah Cannon Center for Blood Cancer, Sarah Cannon Research Institute, discusses the relationship between chimeric antigen receptor (CAR) T-cell therapy and stem cell transplant.
Dr. Goldberg Discusses Resistance to EGFR TKI Therapy in NSCLC
March 8th 2018Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses testing for and treating resistance to EGFR tyrosine kinase inhibitor (TKI) therapy in non–small cell lung cancer.
Dr. Gieschen on the Side Effects of Radiation Therapy in NSCLC
February 27th 2018Holger L. Gieschen, MD, assistant professor, Department of Radiology, the University of Tennessee Health Science Center, radiation oncologist, West Cancer Center, discusses the safety profile of radiation therapy in patients with non–small cell lung cancers (NSCLC).
This Week in Managed Care: February 23, 2018
February 23rd 2018This week, the top managed care stories included the Trump administration proposed extending the duration of short-term health plans; a report found that CAR T-cell therapies are worth their high price tags; the new issue of Evidence-Based Oncology® examined current issues in immunotherapy.